Sermorelin

Sermorelin is the acetate salt of GHRH(1-29)NH2, the active N-terminal piece of the body's own growth hormone-releasing hormone. It binds pituitary GHRH receptors and triggers physiological, pulsatile GH release, keeping the normal GH–somatostatin–IGF-1 feedback loop intact in a way that straight GH replacement does not. The trade-off is duration: its half-life runs in minutes, not the hours of tesamorelin or CJC-1295, so it needs frequent dosing to keep the pituitary engaged. And it cannot push GH past what the gland is willing to make — a safety feature and a hard ceiling on effect, at the same time.

Sermorelin was approved in an earlier regulatory era, mainly to diagnose GH reserve and treat GHD in children; the adult therapeutic case was always thinner. The branded product, Geref, was pulled by Serono in 2008 — a commercial decision, not a safety one. Today it survives through compounding pharmacies as off-label treatment for adult-onset GH insufficiency. Here is the honest part: the adult evidence is mostly clinical-experience reviews and expert opinion, not modern RCTs. One peer-reviewed review (Walker 2006) argues its physiological mode of action beats direct GH replacement — but that is an argument from mechanism, not a head-to-head trial result. Anyone choosing sermorelin is standing on softer evidentiary ground than tesamorelin sits on.

• Stimulates pituitary GH secretion in adults with GH insufficiency
• Proposed to preserve physiological GH pulsatility better than direct GH replacement
• Historically used to gauge pituitary GH reserve (diagnostic)
• Clinical reports of improved body composition and sleep in adult GHD patients

• Evidence base in adults is observational and review-level — no modern large RCTs
• Compounding pharmacy products vary in purity and sterility standards
• Injection-site reactions; flushing; headache reported
• Antibody development to sermorelin has been reported with repeated dosing
• Not directly regulated by the FDA post-discontinuation of Geref; quality depends on compounder
• Any IGF-1-raising therapy carries theoretical oncological caution in predisposed individuals

Prescription. Available in the US only via prescription or a compounding pharmacy.

Goals studied: GH / IGF-1 support, Body composition, Sleep & recovery

Is sermorelin still FDA-approved?

The branded product Geref was voluntarily discontinued by its manufacturer in 2008. Sermorelin itself was not banned — it can still be legally compounded and prescribed by licensed physicians in the US for appropriate patients.

How does sermorelin compare to CJC-1295?

Both are GHRH analogs, but CJC-1295 was designed to be far longer-acting through albumin conjugation. Sermorelin has a short half-life requiring more frequent dosing. Neither has the RCT evidence base that tesamorelin has.

Can sermorelin improve sleep?

GH secretion is closely linked to slow-wave sleep, and stimulating the pituitary GH axis has biological rationale for affecting sleep architecture. However, there are no RCTs specifically demonstrating sleep improvement from sermorelin in humans — this is an area of clinical interest without rigorous confirmation.

1. [1]
   Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

   Walker RF · Clinical Interventions in Aging · 2006 · PMID 18046908 · model: human

   A clinical review arguing that sermorelin, by stimulating physiological pulsatile GH release, offers advantages over direct GH replacement in adult-onset GH insufficiency — though the argument is mechanistic rather than RCT-supported.